Loading
Life sciences · Journal article
Biomedicines · October 6, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background: Chimeric antigen receptor (CAR) T-cell therapy for solid tumors is limited by inadequate T-cell persistence and tumor infiltration, as well as treatment-associated cytokine release syndrome (CRS). To address these challenges, we developed a metabolically rewired CAR T-cell (MRCAR) platform by co-expressing adenosine deaminase 1 (ADA1) and CD26 in CAR T cells. Methods: MRCAR T cells were generated using either GPC3-targeted CARs for hepatocellular carcinoma (HCC) or HER2-targeted CARs for breast cancer. For HCC, we further evaluated constructs with and without enforced IL-15 expression to boost T-cell function. Results: In vitro, IL-15–expressing GPC3-MRCAR T cells exhibited enhanced proliferation, sustained effector function, reduced exhaustion, and superior cytotoxicity following repeated antigen stimulation compared with conventional CAR T cells. CD26 expression significantly enhanced CAR T-cell invasiveness in transwell assays and promoted tumor infiltration in vivo in both tumor models. ADA1 expression enhanced CAR T-cell persistence and was associated with increased frequencies of memory and stem-like T-cell populations in vivo. Notably, although IL15-GPC3-CAR T-cell treatment increased antitumor activity, it also caused high mortality and systemic inflammation in Huh7 tumor-bearing mice, whereas incorporation of ADA1 and CD26 into MRCAR T cells significantly improved survival and reduced serum levels of IL-6, IFN-γ, and TNF-α. Mechanistically, conventional IL-15–expressing GPC3-CAR T cells induced proinflammatory M1-like macrophage activation, whereas MRCAR T cells markedly suppressed this inflammatory response. Conclusions: Collectively, these results indicate that metabolic rewiring via ADA1 and CD26 enhances CAR T-cell expansion, tumor infiltration, persistence, and safety, supporting the MRCAR platform as a promising strategy to improve both efficacy and tolerability of CAR T-cell therapy for solid tumors.